glp 1 kidney disease Frontiers Recommendations for SGLT2i versus GLP-1

Her background is in clinical pharmacy, and now she's an obesity director at Novo Nordisk

59 TrujilloJ

If the answer is yes, the medication may not be creating new anxiety

At the very same time, modern medicine is experiencing a paradigm shift in metabolic care, driven by drugs that were once considered diabetes medications but are now reshaping the way we think about weight, inflammation, and even aging: GLP-1 receptor agonists (GLP-1 RAs)

10.1016/j.jclinane.2023.111091 [DOI] [PubMed] 23.Santos LB, Mizubuti GB, da Silva LM, Silveira SQ, Nersessian RSF, Abib ACV et al (2024) Effect of various perioperative semaglutide interruption intervals on residual gastric content assessed by esophagogastroduodenoscopy: a retrospective single center observational study

Profiles of patients who may benefit from GLP-1RA plus SGLT2i combination therapy The presented cumulative evidence supports the benefits of GLP-1RA plus SGLT2i combination therapy on metabolic-cardiovascular-renal disease in patients with T2DM